Earnings call transcripts

Management framed strong demand and SELECT’s cardiovascular result as expanding semaglutide’s value, while emphasizing that supply and launch pace remain deliberately constrained.

Management framed the quarter around accelerating product adoption, stronger go-to-market execution, and a return to growth with improved cash generation.

Management framed 2023 as a year of execution, tempering near-term expectations while emphasizing APAC strength and longer-term U.S. adoption potential. U.S.

Management framed the quarter as a channel-inventory reset masking underlying demand, while cost reductions and a stronger U.S. and fast-charging mix support year-end breakeven ambitions.

Management framed the quarter as a liquidity and deposit-franchise stress test that reinforced a more conservative balance-sheet and capital plan.

Management framed recovery as a gradual, U-shaped process, with profits not expected to recover notably until 2024. 82% of Q1 new unsecured loans were in the top three credit tiers, versus 41% a year earlier.

Management framed growth as increasingly constrained by supply, while stressing sustained GLP-1 demand and investment to expand capacity.

Management framed the quarter as broad-based ICL share gains despite weak refractive markets, with China recovered and U.S. launch investments still building adoption.

Management framed 2023 as a transition toward scale and profitability, with cost cuts, product launches and channel normalization underpinning second-half confidence.

Management framed recovery as U-shaped but contingent on SMB conditions and credit-enhancement negotiations, prioritizing asset quality and margin sustainability over near-term growth.

Management framed 2023 around strong GLP-1 demand and capacity expansion, while stressing supply limits and unusually high uncertainty around market growth.

Management framed 2023 as an investment year, with confidence in China’s recovery and a sharper push to build U.S. EVO adoption. $5 million of Q4 sales were removed amid China’s COVID-related disruption.